Guselkumab for the treatment of severe plaque psoriasis in a schizophrenia patient

Nicoletta Bernardini,¹ Nevena Skroza,¹ Elisabeth Prevete,² Federica Marrarra,¹ Ilaria Proietti,¹ Ersilia Tolino,¹ Alessandra Mambrini,¹ Giovanni Rossi,¹ Salvatore Volpe,¹ Giuseppe Bersani,³ Concetta Potenza¹

¹Dermatology Unit “D. Innocenzi”, Polo Pontino, Sapienza University of Rome; ²Department of Human Neuroscience, Sapienza University of Rome; ³Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy

Abstract

A wide range of comorbid conditions are associated with psoriasis, many studies have drawn attention to a higher prevalence of psychiatric comorbidities in psoriatic population. Herein, we present a case of a Caucasian 44-years-old male suffering from a severe schizophrenia, who received guselkumab, a human monoclonal antibody targeting the p40 subunit of IL-23, for the treatment of moderate-to-severe plaque psoriasis. After 3 months, the patient reached complete resolution of psoriasis without any side effects, maintained at 6 months follow up visit. Some studies have highlighted the hypothesis that an hyperactivation of immune response appears to be one of the main mechanisms underlying the increased risk of this association. In particular, the axis il-17/IL-23 plays a central role in the pathogenesis of this disease. Further research will be needed to assess whether anti-IL23 drugs could be a more suitable therapeutic option in psoriatic patients with schizophrenia.

Introduction

Psoriasis is an immune-mediated disorder, affects approximately 2-3% of general population.¹ Angiogenesis plays a key role in the pathogenesis of psoriasis and the formation of new blood vessels is an early event in the development of psoriatic plaque and recurrences.³

A wide range of comorbid conditions are associated with psoriasis, in particular cardiovascular disease, metabolic syndrome, and hypertension. Moreover, many studies have drawn attention to a higher prevalence of psychiatric comorbidities in psoriatic population.³

Case report

Herein, we report the case of a 44-years-old male suffering from a severe form of psoriasis since the age of 15. He had a long history of chronic severe schizophrenia. At the time of the evaluation, his self-care was very scarce, and he was experiencing the worsening of pre-existing psychotic symptoms. The clinical exam revealed a moderate-to-severe flare of plaque type psoriasis coinciding with an exacerbation of his psychiatric pathology. Sharply demarcated erythematous plaques covered by silvery lamellar scales were localized on legs, arms and trunk configuring a flare of plaque type psoriasis with psoriasis area severity index (PASI) of 36 (Figure 1a).

In agreement with the psychiatrists, guselkumab, a human monoclonal antibody targeting the p40 subunit of IL-23, was started at dosage of 100 mg subcutaneously initially, after 4 weeks, and then every 8 weeks. After 1 month of treatment an improvement was observed with a PASI decrease from a score of 36 to 7. After 3 months, the patient reached complete resolution of psoriasis without any side effects (Figure 1b), maintained at 6 months follow up visit.

Discussion

Schizophrenia is a chronic and high disabling mental disorder, defined by the presence of psychotic symptoms, which include both positive and negative symptoms.⁴ The pathogenesis is not completely understood and is commonly considered multifactorial.⁴ Amongst supposed mechanism underlying schizophrenia, the role of the immune system has recently been suggested.⁵ We present the case of a patient with a coexisting diagnosis of psoriasis and schizophrenia. To our knowledge, there are only few case reports dealing this association. Miyaoaka et al. have described three cases of patients in whom exacerbated symptoms of psoriasis coincided with the emergence of schizophrenia. A recent meta-analysis showed a 1.83-fold increased risk of psoriasis among patients with schizophrenia compared with subjects without schizophrenia. Similarly, another meta-analysis indicated that the risk of developing psoriasis in schizophrenic patients is 41% higher than in health subjects.⁷

An hyperactivation of immune response appears to be one of the main mechanisms underlying this increased risk. In particular, the axis il-17/IL-23 plays a central role in the pathogenesis of psoriasis and representing an important therapeutic target.⁸ More recently some studies have also highlighted the hypothesis that immune system and inflammation may have a role in psychotic spectrum disorders and schizophrenia.⁸ Furthermore, the role of pro-inflammatory cytokines and Th17 signaling pathway in the pathogenesis of schizophrenia has also been suggested. According to some evidence, Dopamine stimulates the secretion of
il-17 in some psychiatric pathologies, such as in psychotic disease. The dopamine (DA) hypothesis is classically considered to explain psychotic symptoms in schizophrenia, with positive symptoms suggested being linked to the high dopamine levels in the striatum, and negative symptoms associated with the reduced dopamine function in both prefrontal cortex and meso-cortical pathway.

Therefore, dopaminergic inhibitors represent the milestone in the treatment of disease. The presence of this common immunological substrate might be possible that biologic agents targeting on immune molecules may provide new therapeutic alternatives for schizophrenia.

Interestingly, a common genetic susceptibility has been assumed between psoriasis and schizophrenia. In correspondence of chromosome 6 there are regions of major susceptibility both for psoriasis and for schizophrenia, on 6p21.3 and 6p22.1, respectively.  

Conclusions

Increased serum levels of IL23, which underlies the pathogenetic mechanism of schizophrenia, could support the use of IL23-inhibiting drugs. However, further research will be needed to assess whether anti-IL23 drugs could be a therapeutic option in patients with a psychiatric comorbidity such as schizophrenia.

In conclusion, guselkumab, was effective and safe in the treatment of psoriasis in a schizophrenic patient.

References

1. Rangi G, Campanati A, Diotallevi F et al. A. Novel Therapeutic Approaches and Targets for Treatment of Psoriasis. Curr Pharm Biotechnol. 2021
2. Errore. Riferimento a collegamento ipertestuale non valido., Errore. Riferimento a collegamento ipertestuale non valido., Adalimumab Modulates Angiogenesis in Psoriatic Skin, European Journal of Inflammation, 2013 May 1
3. Ungprasert P, Wijarnpreecha K et al. Patients with schizophrenia have a higher risk of psoriasis: A systematic review and meta-analysis. Psychiatry Res. 2018 Jan
4. Correll CU, Schooler NR. Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment. Neuropsychiatr Dis Treat. 2020 Feb 21
5. Stilo SA, Murray RM. Non-Genetic Factors in Schizophrenia. Curr Psychiatry Rep. 2019 Sep 14
6. Goldsmith DR, Rapaport MH et al. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry. 2016 Dec
7. Borovcanin M, Jovanovic I et al. Increase systemic levels of IL-23 as a possible constitutive marker in schizophrenia. Psychoneuroendocrinology. 2015 Jun
8. Yu S, Yu CL, Huang YC et al. Risk of developing psoriasis in patients with schizophrenia: a nationwide retrospective cohort study. J Eur Acad Dermatol Venereol. 2017 Sep
9. Radhakrishnan R, Kaser M et al. The Link Between the Immune System, Environment, and Psychosis. Schizophr Bull. 2017 Jul
10. Yin X, Wineinger NE et al. Common susceptibility variants are shared between schizophrenia and psoriasis in the Han Chinese population. J Psychiatry Neurosci. 2016 Oct